The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling
Open accessAbstract
Purpose: Nasopharyngeal cancer (NPC) is a common cancer in Hong Kong, and relapse can occur frequently. Using protein chip profiling analysis, we aimed to identify serum biomarkers that were useful in the diagnosis of relapse in NPC. Experimental Design: Profiling analysis was performed on 704 sera collected from 42 NPC patients, 39 lung cancer patients, 30 patients with the benign metabolic disorder thyrotoxicosis (TX), and 35 normal individuals (NM). Protein profile in each NPC patient during clinical follow up was correlated with the relapse status. Results: Profiling analysis identified two biomarkers with molecular masses of 11.6 and 11.8 kDa, which were significantly elevated in 22 of 31 (71%) and 21 of 31 (68%) NPC patients, respectively, at the time of relapse (RP) as compared with 11 patients in complete remission (CR; RP versus CR, P = 0.009), 30 TX (RP versus TX, P < 0.001), or 35 NM (RP versus NM, P < 0.001). The markers were also elevated in 16 of 39 (41%) lung cancer patients at initial diagnosis. By tryptic digestion, followed by tandem mass spectrometry fragmentation, the markers were identified as two isoforms of serum amyloid A (SAA) protein. Monitoring the patients longitudinally for SAA level both by protein chip and immunoassay showed a dramatic SAA increase, which correlated with relapse and a drastic fall correlated with response to salvage chemotherapy. Serum SAA findings were compared with those of serum Epstein-Barr virus DNA in three relapsed patients showing a similar correlation with relapse and chemo-response. Conclusions: SAA could be a useful biomarker to monitor relapse of NPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Cited by
Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool
Diamandis, E. P. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400007-mcp200 · Cited by 631
Human body fluid proteome analysis
Hu, S., Loo, J. A., & Wong, D. T. (2006) · PROTEOMICS · doi:10.1002/pmic.200600284 · Cited by 533
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Hortin, G. L. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.069252 · Cited by 351
Progress in protein and antibody microarray technology
Angenendt, P. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03392-1 · Cited by 289
Contribution of oncoproteomics to cancer biomarker discovery
Cho, W. C. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-25 · Cited by 268
Self-citation
Metadata
- Authors
- Cho, W. C. S., Yip, T. T. C., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K. C., Yip, T.-T., Lau, W.-H., Au, J. S. K., Law, S. C. K., Cheng, W.-W., Ma, V. W. S., & Lim, C. K. P.
- Venue
- Clinical Cancer Research
- Published
- 2004-01-01
- Volume
- 10
- Issue
- 1
- Pages
- 43-52
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2143233121
- Cited by
- 207
- References
- 1
- FWCI
- 23.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-0413-3
- The paper
- Cho, W. C. S., Yip, T. T. C., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K. C., Yip, T.-T., Lau, W.-H., Au, J. S. K., Law, S. C. K., Cheng, W.-W., Ma, V. W. S., & Lim, C. K. P. (2004). Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-0413-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.